Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SOLIRIS vs ADUHELM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.
Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.
Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis,Atypical hemolytic uremic syndrome (a HUS) to inhibit complement-mediated thrombotic microangiopathy,Generalized myasthenia gravis (g MG) in adult patients who are anti-acetylcholine receptor antibody-positive,Neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 antibody-positive
Treatment of Alzheimer's disease (FDA approved for patients with mild cognitive impairment or mild dementia stage of disease)
600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.
10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.
Terminal elimination half-life: approximately 11.3 ± 3.4 days (range 8–18 days) following biweekly dosing. This supports a dosing interval of every 2 weeks for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Terminal elimination half-life is approximately 26 days (range 19–34 days), supporting monthly intravenous dosing. The long half-life reflects the slow clearance of Ig G1 monoclonal antibodies.
Eculizumab is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Aducanumab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous Ig G. No specific cytochrome P450 enzymes are involved.
Eculizumab is not metabolized by cytochrome P450 enzymes; it is degraded via general protein catabolism. Clearance is primarily through the reticuloendothelial system; renal excretion of intact drug is negligible (<1%). No biliary or fecal excretion data are available in humans.
ADUHELM is eliminated primarily via catabolism into small peptides and amino acids. No renal or biliary excretion of intact monoclonal antibody is expected. Clearance is via the reticuloendothelial system; approximately 97% is metabolized, with <3% excreted as intact antibody in urine.
Eculizumab is a recombinant humanized monoclonal antibody; it does not bind to serum proteins significantly. Protein binding is negligible (approximately 0%), as it is a large protein molecule.
Approximately 99% bound, primarily to endogenous Ig G (via Fc Rn binding) and other plasma proteins; specific binding proteins include Fc Rn.
Volume of distribution at steady state: approximately 7.5 L (0.11 L/kg in a 70 kg adult), indicating distribution primarily within the vascular and interstitial spaces, consistent with limited extravascular distribution of a large monoclonal antibody.
Volume of distribution is approximately 6.8 L (central compartment), equivalent to plasma volume; does not distribute extensively into tissues due to large molecular size. In L/kg: ~0.1 L/kg for a 70 kg patient.
Intravenous administration only; bioavailability is 100% by the intravenous route. No oral or other routes are available.
Intravenous administration results in 100% bioavailability. No subcutaneous or oral formulation is available; thus no bioavailability for other routes.
No dose adjustment required based on GFR. Eculizumab is not renally cleared.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease.
No specific guidelines for hepatic impairment; likely no adjustment needed as metabolism is not hepatic.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
For a HUS: weight-based: 5 to <10 kg: 300 mg; 10 to <20 kg: 600 mg; 20 to <30 kg: 600 mg; 30 to <40 kg: 900 mg; >=40 kg: 900 mg. Induction: weekly x4, then dose 1 week later, then maintenance every 2 weeks. For PNH: not approved in children <18 years.
Safety and efficacy have not been established in pediatric patients. No recommended dosing available.
No specific dose adjustment. Monitor for infections, especially meningococcal, as elderly may have increased susceptibility.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy observed.
SOLIRIS increases the risk of meningococcal infections. Patients must receive meningococcal vaccination at least 2 weeks prior to administration, unless the risks of delaying therapy outweigh the risks of developing a meningococcal infection. Patients should be monitored for early signs of meningococcal infection and evaluated immediately if infection is suspected.
WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA). Aducanumab can cause ARIA, including ARIA-E (edema/effusion) and ARIA-H (hemorrhage/hemosiderin deposition), which can be serious and life-threatening. ARIA generally occurs within the first 8 doses. Monitoring with MRI is required prior to and during treatment.
Increased susceptibility to meningococcal infections due to complement inhibition; vaccinate and monitor,Other Neisseria species and encapsulated bacteria infections (e.g., Streptococcus pneumoniae, Haemophilus influenzae type b); consider vaccination,Infusion reactions: including anaphylaxis and hypersensitivity; discontinue if severe,Monitoring for hemolysis in PNH patients: discontinue if evidence of severe hemolysis,Monitoring for thrombotic microangiopathy (TMA) in a HUS patients: discontinue if TMA complications occur
Amyloid-related imaging abnormalities (ARIA), including ARIA-E and ARIA-H,Hypersensitivity reactions including angioedema and urticaria,Risk of seizures (reported in clinical trials),Concomitant use of antithrombotic medications may increase risk of intracranial hemorrhage
Unresolved serious Neisseria meningitidis infection,Patients not currently vaccinated against Neisseria meningitidis (unless delays in therapy outweigh risks),Known hypersensitivity to eculizumab or any of its excipients
Known hypersensitivity to aducanumab or any excipients of ADUHELM
No clinically significant food interactions reported; administer intravenously over 35 minutes.
No specific food interactions reported. Patients should maintain a balanced diet as part of overall health management. Avoid grapefruit juice if taking other medications metabolized by CYP3A4, though aducanumab is not metabolized by CYP enzymes.
First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections due to complement inhibition; monitor for meningococcal and other infections. No known structural teratogenicity.
No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal reproductive studies available. Use only if benefit outweighs potential risk.
No human data; eculizumab is a large monoclonal antibody likely to be present in minimal amounts in breast milk due to molecular size; M/P ratio unknown. Caution advised.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Aducanumab is a large Ig G molecule; likely excreted into milk in low amounts. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with mother's clinical need.
No formal studies; pharmacokinetics may be altered due to increased plasma volume and renal function; consider monitoring drug levels if available, but no specific dose adjustment recommended.
No pharmacokinetic data during pregnancy. Dose adjustments not established. Administer same dose as non-pregnant adults (10 mg/kg IV monthly after titration) unless significant infusion reactions occur.
Administer meningococcal vaccines at least 2 weeks prior to first dose; vaccinate against Neisseria meningitidis serogroups A, C, Y, W-135 and serogroup B. Monitor for hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH) after discontinuation. Do not administer live vaccines. Infusion reactions may occur; premedicate with antihistamines and corticosteroids if needed. Eculizumab increases risk of serious infections, especially encapsulated bacteria. Prescribe prophylactic antibiotics if vaccination cannot be given 2 weeks prior. Monitor LDH, hemoglobin, and reticulocyte count in PNH.
ADUHELM (aducanumab-avwa) is a monoclonal antibody targeting aggregated forms of beta-amyloid. It is indicated for Alzheimer disease. Confirmation of amyloid beta pathology via PET or CSF is required before initiation. Titration over 6-8 months is mandatory to reduce risk of amyloid-related imaging abnormalities (ARIA). Monitor for ARIA with MRI prior to the 7th and 12th infusions; suspend dosing if ARIA is detected. Adverse effects include ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition). Coadministration with anticoagulants may increase risk of ARIA-H. Assess for hypersensitivity reactions. No specific reversal agent is available.
You must receive meningococcal vaccines at least 2 weeks before starting treatment.,This medication increases your risk of serious infections, especially meningitis.,Report any signs of infection such as fever, headache with stiff neck, or rash immediately.,Do not receive live vaccines while on this medication.,If you stop treatment, your healthcare provider will monitor you for red blood cell breakdown.,Promptly report any bruises, bleeding, or signs of injection site reaction.
This drug is for patients with mild cognitive impairment or mild Alzheimer disease confirmed by amyloid PET or CSF testing.,Treatment requires intravenous infusion every 4 weeks, with dose titration over at least 6 months.,MRI scans are needed before and during treatment to monitor for brain swelling or small bleeds (ARIA).,Tell your doctor immediately if you experience headache, confusion, dizziness, vision changes, nausea, or seizures.,Avoid blood thinners like warfarin, apixaban, or rivaroxaban unless prescribed; they may increase bleeding risk.,Do not drive or operate heavy machinery if you experience dizziness or visual disturbances.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Store vials in refrigerator and protect from light; do not freeze or shake.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SOLIRIS vs ADUHELM, answered by our medical review team.
SOLIRIS is a Monoclonal Antibody that works by Soliris (eculizumab) is a monoclonal antibody that specifically binds to complement protein C5, thereby inhibiting its cleavage to C5a and C5b and preventing the formation of the membrane attack complex (MAC). This action blocks terminal complement-mediated inflammation and cell lysis.. ADUHELM is a Anti-Amyloid Beta Monoclonal Antibody that works by Aducanumab is a human monoclonal antibody that selectively binds to aggregated soluble and insoluble forms of amyloid beta, thereby reducing amyloid plaque deposition in the brain.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SOLIRIS and ADUHELM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SOLIRIS is: 600 mg intravenous over 35 minutes weekly for 4 weeks, then 900 mg 1 week later, followed by 900 mg every 2 weeks for paroxysmal nocturnal hemoglobinuria (PNH). For atypical hemolytic uremic syndrome (a HUS): 900 mg intravenous over 35 minutes weekly for 4 weeks, then 1200 mg 1 week later, followed by 1200 mg every 2 weeks.. The standard adult dose of ADUHELM is: 10 mg/kg intravenous infusion over approximately one hour, once every four weeks. Dosing initiation requires a titration schedule: first three doses at 1 mg/kg, fourth dose at 3 mg/kg, fifth dose at 6 mg/kg, and subsequent doses at 10 mg/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SOLIRIS and ADUHELM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SOLIRIS is classified as Category C. First trimester: No adequate human data; animal studies show no evidence of teratogenicity. Second and third trimesters: Both mother and fetus may have increased risk of infections. ADUHELM is classified as Category C. No adequate and well-controlled studies in pregnant women. Based on mechanism of action (anti-amyloid beta monoclonal antibody), potential for fetal harm is unknown. No animal repr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.